Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Benjamin Chalopin

Benjamin Chalopin


Development of protein display approaches for antibody selection


I obtained my PhD at Nantes University in France. During my PhD, I worked on ribosome display selection of anti-CD38 Affitins (artificial proteins binding to antigens) for PET imaging of multiple myeloma. Thereafter, I started my first postdoc at Commissariat a l’Energie Atomique (CEA; Paris, Frankrijk). Here, my project was to use yeast display for the selection of antibodies against SARS-CoV2. 

In June 2023, I joined the Princess Máxima Centrum as a postdoc for the Protein Facility. My main focus is to set up protein display approaches (yeast and phage display) combined with deep sequencing for high-throughput selection of antibodies and nanobodies with favorable properties for promising targets in pediatric oncology. The selected antibodies and nanobodies can be used in various applications, such as PET imaging, drug conjugation, or CAR-T cell therapies, to improve outcomes for children with cancer.

  • Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift

    • jan. 2022
    • Adrien, Laroche, et al
    • mAbs
  • Immunopet in multiple myeloma—what? So what? now what?

    • jan. 2020
    • Clément, Bailly, et al
    • Cancers
  • Affitins: Ribosome Display for Selection of Aho7c-Based Affinity Proteins

    • jan. 2020
    • Valentina, Kalichuk, et al
  • What is the best radionuclide for immuno-PET of multiple myeloma? A comparison study between89 zr-and64 cu-labeled anti-CD138 in a preclinical syngeneic model

    • feb. 2019
    • Clément, Bailly, et al
    • International journal of molecular sciences
  • Comparison of immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma

    • jan. 2018
    • Clément, Bailly, et al
    • Oncotarget
View all publications